Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Bayer bails on Vividion tumor drug in early-stage clear-out
Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of its buyout of Vividion.
James Waldron
Nov 12, 2025 8:10am
Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus
Nov 6, 2025 1:26pm
AstraZeneca drops MASH drug over disappointing data
Nov 6, 2025 5:21am
TScan lays off 30% of workforce, halts solid tumor TCR trial
Nov 3, 2025 8:25am
Nanobiotix finds new way to source cash from J&J-partnered drug
Oct 31, 2025 6:05am
Sensei drops sole clinical-stage cancer drug, plans layoffs
Oct 30, 2025 9:52am
